Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roxane, Ranbaxy Launch Biaxin Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

Clarithromycin immediate-release generics enter the market following expiration of Abbott’s compound patent; litigation over other patents is ongoing.

You may also be interested in...



Teva's Biaxin XL Generic Would Irreparably Harm Abbott, Court Rules

Teva is preliminarily enjoined from launching extended-release clarithromycin pending a ruling on the merits of patent infringement claims. A Chicago federal judge preliminarily rules that only one of three Abbott patents at issue is valid. Teva expects to file an expedited appeal to the Federal Circuit.

Teva's Biaxin XL Generic Would Irreparably Harm Abbott, Court Rules

Teva is preliminarily enjoined from launching extended-release clarithromycin pending a ruling on the merits of patent infringement claims. A Chicago federal judge preliminarily rules that only one of three Abbott patents at issue is valid. Teva expects to file an expedited appeal to the Federal Circuit.

Teva’s Biaxin XL Generic Barred From Launch Pending May 26 Hearing

A temporary restraining order prevents Teva from launching its extended-release generic upon the May 23 expiration of the clarithromycin compound patent. Abbott already has gotten a jump on potential generic versions of immediate-release Biaxin with an “authorized” generic sold through Dava.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel